We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App




Novel Non-Invasive Liquid Biopsy Assay Enables Monitoring of Multiple Myeloma Patients

By LabMedica International staff writers
Posted on 28 Sep 2023

Multiple myeloma ranks as the second most common type of blood cancer, affecting a global population of over 170,000. More...

This cancer targets plasma cells, which primarily exist in the bone marrow, and leads to their uncontrolled growth. Managing multiple myeloma is particularly challenging because patients often experience relapses, making it an incurable condition. A crucial aspect in monitoring this disease is the concept of Minimal Residual Disease (MRD), which refers to the undetectable traces of cancer cells that remain in the bone marrow post-treatment and can eventually cause a relapse. MRD status serves as a vital indicator of how well a treatment is working and could influence future treatment choices.

To enhance the management of multiple myeloma, especially as new treatments are being developed, there's an immediate need for more sensitive MRD tests that can be done through blood samples. Current tests usually require bone marrow samples, which are invasive to collect and not practical for regular check-ups. To fulfill this need, Sebia (Paris, France) has launched M-inSight, its serum-based MRD test for monitoring multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, which is a CAP-accredited, CLIA-licensed clinical laboratory and part of the Sebia Group.

M-inSight is a personalized, targeted mass spectrometry assay that is designed to detect the monoclonal protein (M-protein) secreted by the patient’s tumor cells in serum with unprecedented sensitivity. The technology is based on clonotypic peptides mass spectrometry, which avoids the interference with the polyclonal background leading to an ultra-sensitive test. Currently, Sebia is the only global partner covering the process of M-protein testing from initial detection to MRD and is also developing other liquid biopsy tests such as Circulating Tumor Cells (CTC) and new biomarkers.

“We are proud to launch M-inSight to improve the management of multiple myeloma and quality of life for patients, as well as assisting in the drug development and validation process”, said Dr. Pierre Sonigo, chief scientific officer at Sebia. “By testing in serum with equivalent sensitivity to bone marrow, we will solve current challenges in multiple myeloma MRD-testing, allowing for a more frequent and reliable monitoring of response to treatment.”

Related Links:
Sebia


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.